Market Place
Sourcing Support
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
07 Dec 2023 //
BUSINESSWIRE
Neurocrine Presents Parkinson`s Disease Patient Characteristics From ONGENTYS
24 Oct 2022 //
PRNEWSWIRE
Neurocrine Presents Analysis of ONGENTYS Capsules Effect on COMT Activity
15 Sep 2022 //
PRNEWSWIRE
Bial Portela & Companhia Ontilyv (opicapone) Receives Approval in Europe
07 Mar 2022 //
EMA
Bial Portela`s Biologic Optilyv (Opicapone) Receives Approval in Europe
07 Mar 2022 //
EMA
New study investigating impact of ONGENTYS at the MDS Virtual Congress 2021
14 Sep 2021 //
PHARMIWEB
BIAL and Recipharm expand long-term supply agreement for opicapone API
01 Oct 2020 //
PRESS RELEASE
Neurocrine Announces Once-Daily ONGENTYS (opicapone) Now Available in the U.S.
14 Sep 2020 //
PRNEWSWIRE
Neurocrine Biosciences Presents Data Demonstrating Efficacy of Approved ONGENTYS
11 Sep 2020 //
PRNNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.